US Business Was Impacted By Seasonality In Q1FY25: Aurobindo Pharma | CNBC TV18

(10:40)

Aurobindo Pharma: An Apple In A Basket Of Oranges?

(8:12)

Aurobindo Pharma Corporate Film

(13:14)

'Big Bull' Rakesh Jhunjhunwala Questions Aurobindo Pharma's Management

(4:56)

Aurobindo Pharma USA recalls 2 lots of blood medication

(39)

Aurobindo Pharma | Corporate Video | Raasta Studios

(8:42)

Stocks on Radar: Aurobindo Pharma, Fortis Healthcare, Laurus Labs, TCS on Focus | December 23

(3:11)

Aurobindo Pharma Announces Entry Into The Domestic Formulations Business

(46)

U.S. FDA Issues 10 Observations To Aurobindo Pharma Under Form 483 | Halftime Report | CNBC-TV18

(2:31)

Aurobindo pharma - buy buy buy

(8:11)

We Have Made Significant Inroads In Mid-Tier Pharma Companies: Indegene | CNBC TV18

(4:37)

Citi Downgrades Aurobindo Pharma To Sell; Sees No Material Improvement In US Generic Dynamics

(1:13)

See A Lot Of Potential In The Biologics Space: Aurobindo Pharma | N18V | CNBC TV18

(7:48)

Pharma Stocks See A Big Rally In 2023 With Aurobindo Pharma Up 93%, Lupin Up 74% | CNBC TV18

(4:33)

OIA On Eugia Unit III Doesn't Really Impact Aurobindo's Biz \u0026 Sales Should Continue: Systematix Grp

(10:)

Would Like To Backward Integrate Into Contract Development: Aurobindo Pharma | CNBC TV18

(9:4)

Aurobindo Pharma Surges After Its Arm CuraTeQ Gets EMA Nod For Filgrastim Biosimilar | CNBC TV18

(1:13)

Aurobindo Pharma Ltd Q1 FY2024-25 Earnings Conference Call

(53:43)

Aurobindo Pharma Surges As Eugia Steriles' Andhra Facility Gets First US FDA Approval For Injectable

(1:37)

Aurobindo Pharma: Aurobindo Pharma is Hiring MSc, BPharm, and MPharm Candidates for Quality Control

(1:36)

Aurobindo Pharma Under Pressure After US FDA Issues Warning Letter For Eugia Unit III | CNBC TV18

(2:35)

APL Film Short

(8:33)

Aurobindo Pharma gets VAI classification, US FDA gives nod to two facilities

(1:52)

Aurobindo Pharma Q1. Total Income Rises 12.9%

(52)

StorFast® - Aurobindo Pharma Testimonial

(5:20)